Zevra’s main revenue driver is a drug called MIPLYFFA, which is used to treat the rare progressive genetic disorder Niemann-Pick Disease Type C (NPC which causes cholesterol and fats to build up in …
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market
view original post